Lipella Pharmaceuticals Enters Material Definitive Agreement

TL;DR

Lipella Pharma signed a big deal on March 13th, details TBD.

AI Summary

Lipella Pharmaceuticals Inc. announced on March 15, 2024, that it entered into a material definitive agreement on March 13, 2024. The filing does not disclose specific details of the agreement or any associated dollar amounts.

Why It Matters

This filing indicates a significant new agreement for Lipella Pharmaceuticals, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about its nature and potential impact.

Key Players & Entities

• Lipella Pharmaceuticals Inc. (company) — Registrant
• March 15, 2024 (date) — Date of Report
• March 13, 2024 (date) — Earliest event reported

FAQ

Key Financial Figures

• $0.0001 — h registered Common Stock, par value $0.0001 per share LIPO The Nasdaq Stock Mar
• $100,000 — f Drs. Kaufman and Chancellor purchased $100,000 of shares of common stock of the Compan
• $0.6901 — on Stock"), in cash from the Company at $0.6901 per share, based on the official closin

Filing Documents

• g084127_8k.htm (8-K) — 34KB
• g084127_ex10-1.htm (EX-10.1) — 40KB
• g084127_ex10-2.htm (EX-10.2) — 56KB
• 0001753926-24-000545.txt ( ) — 320KB
• lipo-20240315.xsd (EX-101.SCH) — 3KB
• lipo-20240315_lab.xml (EX-101.LAB) — 33KB
• lipo-20240315_pre.xml (EX-101.PRE) — 22KB
• g084127_8k_htm.xml (XML) — 4KB

01 Entry

Item 1.01 Entry into a Material Definitive Agreement. On March 13, 2024, Lipella Pharmaceuticals Inc. (the "Company") entered into Affiliate Stock Purchase Agreements (the "Agreements") with each of Jonathan H. Kaufman, the Company's Chief Executive Officer and Chairman of its board of directors, and Michael B. Chancellor, the Company's Chief Medical Officer and a member of its board of directors, pursuant to which each of Drs. Kaufman and Chancellor purchased $100,000 of shares of common stock of the Company, par value $0.0001 per share (the "Common Stock"), in cash from the Company at $0.6901 per share, based on the official closing price of The Nasdaq Stock Market LLC for the Common Stock on March 13, 2024, resulting in the issuance of 144,906 shares of Common Stock to each of Drs. Kaufman and Chancellor. The Agreements contain customary representations, and warranties for transactions of this type. The forgoing descriptions of the Agreements are qualified in their entirety by reference to the full text of each such agreement, which are filed hereto as Exhibits 10.1 and 10.2, and incorporated herein by reference.

01 Financial

Item 9.01 Financial (d) Exhibits Exhibit No. Description 10.1 Affiliate Stock Purchase Agreement, dated as of March 13, 2024, by and between the Company and Jonathan Kaufman. 10.2 Affiliate Stock Purchase Agreement, dated as of March 13, 2024, by and between the Company and Michael Chancellor. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 15, 2024 Lipella Pharmaceuticals Inc. By: /s/ Jonathan Kaufman Name: Jonathan Kaufman Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR